We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bill Floats Extra Exclusivity for Pursuing Rare Disease Indications
Bill Floats Extra Exclusivity for Pursuing Rare Disease Indications
Manufacturers that adapt existing drugs and biologics to treat rare diseases could receive an additional six months of market exclusivity for the original indication under a new bipartisan House bill.